GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Net Issuance of Debt

Nymox Pharmaceutical (Nymox Pharmaceutical) Net Issuance of Debt

: $-0.22 Mil (TTM As of Sep. 2023)
View and export this data going back to 1997. Start your Free Trial

Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive. Nymox Pharmaceutical's net issuance of debt for the three months ended in Sep. 2023 was $-0.79 Mil. Its net issuance of debt for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.22 Mil.


Nymox Pharmaceutical Net Issuance of Debt Historical Data

The historical data trend for Nymox Pharmaceutical's Net Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Issuance of Debt
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.28 -0.27 -0.24 -0.23

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Issuance of Debt Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.05 -0.06 0.69 -0.79

Nymox Pharmaceutical Net Issuance of Debt Calculation

This is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Net Issuance of Debt for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical Net Issuance of Debt Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Net Issuance of Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

Nymox Announces $2 Million Private Placement

By Marketwired 08-02-2023

Nymox Announces Closing of $6.4 Million Financing

By GuruFocusNews GuruFocusNews 04-04-2022

NYMOX Provides Current Update

By Marketwired Marketwired 10-11-2021

Nymox Provides Current Update

By sperokesalga sperokesalga 05-10-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-12-2022

NYMOX Presenting at Torrey Hills Capital Emerging Growth Conference

By GuruFocusNews GuruFocusNews 11-15-2021

May 2023 Market Cap Requirement Update

By GlobeNewswire GlobeNewswire 11-25-2022

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022

Nymox Shareholder Update

By GuruFocusNews GuruFocusNews 12-13-2021